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3ABSTRACT
Background Juvenile Nasopharyngeal Angiofi broma (JNA) is a rare, benign 
tumour affecting adolescent males. Due to its capability to erode bone, JNA can 
be accompanied by life-threatening complications when growing into the cranium. 
The etiology of JNA is unknown, as are the factors determing the variable growth 
patterns of individual tumours. The treatment of choice for JNA is surgery, but 
high recurrence rates or persistent growth are charasteristic. 
Aims The aim of this study was to elucidate factors determing the variable 
outcomes of JNA. For this purpose the various surgical techniques used to resect 
JNA during the past 40 years at the Helsinki University Central Hospital (HUCH) 
were investigated, immunohistochemistry was performed and the gene copy number 
and mRNA expression data of two phenotypically different JNA tumours were 
combined to seek for processes putatively determining their growth pattern. 
Methods Retrospective clinicopathological data of all JNA patients diagnosed 
and treated, during the years 1970–2011, were reviewed. By immunohistochemistry, 
we investigated the cellular distribution and expression levels of C-KIT, C-MYC, 
BMI-1, GLUT-1, tenascin-C, syndecan-1, syndecan-2 and SYK in JNA samples, in 
order to fi nd their possible correlations with clinicopathological factors. Comparative 
genomic hybridisation and gene expression analyses were performed for two 
phenotypically different tumour samples to investigate the possible processes 
leading to more aggressive growth. A gene ontology enrichment analysis for the in 
silico translated proteins of genes with altered gene expression status was performed 
to detect the categories with enrichments.
Results The primary recurrence rate was 37% and correlated with the surgical 
approach used, transpalatal approach linked with higher risk of recurrence, vascularity 
of the tumour and young age of the patient. Contrary to previous reports, C-KIT 
was expressed in both stromal and endothelial cells of JNA samples and was more 
prominent in slit-like vessels. A correlation between its endothelial expression and 
cellular density of the tumour was found. Frequent stromal tenascin-C expression 
had a strong correlation with vessel density and higher tumour stage. When present, 
endothelial GLUT-1 expression correlated with higher tumour stage. SYK expression 
was found to correlate with lower tumour stage.
Between the low and high stage JNA tumours studied, 1245 genes showed at 
least a two-fold- change in their expression. The corresponding proteins of these 
transcripts were enriched in different biological processes, e.g., hypoxia in the low 
stage tumour and signal transduction activity in the high stage tumour.
4Conclusions The type of surgical approach seemed crucial for the outcome. 
Other clinical factors affecting the recurrence rate were young age of the patient and 
vascular density of the tumour. In selective cases of JNA, we could thus carefully 
recommend the consideration of antiangiogenic treatment. Based on our fi nding 
of protein expressions, we suggest that at least C-KIT, tenascin-C, GLUT-1 and 
SYK might be substantial in the growth of JNA by having an effect on tumour 
cellularity, vessel density and the stage of the tumour. Based on our result of GLUT-1 
positivity correlating with higher tumour stage, we suggest that JNAs are not likely 
to be vascular malformations. Although we were able to identify gene expression 
changes that relate to particular biological processes, the assessing of clinically 
relevant molecular profi les of JNA still requires further characterization. In the 
future, combinating molecular profi ling data from several studies will be useful to 
better understand the molecular background of this rare tumour. 
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1 Introduction
1 INTRODUCTION
Juvenile nasopharyngeal angiofi broma (JNA) is a rare tumour with unknown etiology. 
It is considered to be the most common benign neoplasm of the nasopharynx, 
accounting for 0.5 % of all head and neck neoplasms (1, 2). JNA originates from 
the superior margin of sphenopalatine foramen, also serving as the route for the 
sphenopalatine artery, a branch of internal maxillar artery. Histologically JNA is 
composed of various amounts of fi brous stroma, rich in collagen and fi broblasts, and 
numerous blood vessels with different calibers and shapes. Although histologically 
classifi ed as benign, JNA’s growth pattern can be locally destructive and due to its 
capability to erode bone, it can have life-threathning complications, when extending 
intracranially. Also fatal epistaxis and intraoperative massive haemorrhage are 
possible severe complications of JNA.
The extremely rich vascularisation, complex anatomical structures of the cranium 
and the possible aggressive growth pattern of JNA make its treatment a challenge. 
Surgical removal is accepted to be the treatment of choice, and traditionally the 
used approaches have been transpalatal, transmaxillar, Le Fort I osteotomy, 
and infratemporal fossa craniotomy. In recent decades, preoperative selective 
embolization of the feeding arteries has substantially decreased intraoperative 
bleeding and enabled the resection of even the largest tumours. Yet, recurrence 
rates as high as 50% have been associated with JNA, usually thought to be caused 
by persistent growth of the residual tumour. Trying to overcome this conundrum, 
new treatment strategies have been developed. Among these, endoscopic resection 
has gained popularity, due to its minimal invasiveness, low morbidity rate and 
most importantly, typically low rates of recurrence. The consensus is, however, that 
also this approach has its limitations and is not recommended for tumours with 
extensive growth to the cranium or to the cavernous sinuses. 
The pathogenesis and stem cell population of JNA remain unknown. It has even 
been suggested that JNA is not a true neoplasm. A common feature of JNA is strong 
vasculature. Current studies on the proliferation of stromal and vascular components 
of this tumour have supported the hypothesis of angiogenic factors playing a centred 
role in its pathogenesis. This is of great importance, because during the last decade, 
increased understanding of angiogenesis has allowed the development of novel 
therapeutic substances, also considered for use in some selective cases of JNA. 
Uncovering new aspects of the molecular mechanisms of the pathogenesis of JNA 
will hopefully continue to provide future targets for individual treatment strategies 
for JNA patients. 
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2.1 JUVENILE NASOPHARYNGEAL ANGIOFIBROMA
Juvenile nasopharyngeal angiofi broma (JNA) is thought to represent only 0.05–
0.5% of all head and neck tumours. Its incidence is approximately 1:150 000 per 
year, although incidences in Egypt and India have been reported to be slightly 
higher that in USA and Europe (1, 3). Also males with fair-skin and red hair are 
more often affected (4). It is generally thought that the anatomical origin of JNA is 
the superior part of sphenopalatine foramen, in the posterolateral wall of the nasal 
cavity. However, by analyzing CT and MRI data, Lloyd et al. concluded, that the 
site of origin is in pterygopalatal fossa (5). In most cases, JNA receives its blood 
supply from the internal maxillary artery, a branch of external carotid artery, and 
it is suggested that this tumour originates from vascular plexus that remains after 
involution of fi rst branchial artery (6). In selective cases, feeders from internal 
carotid artery may also be present (7). The fact that almost all JNA cases occur 
in young males, is postulated to be explained by the impact of androgens and the 
precence of hormonal receptors expressed in this tumour (8–10). 
HISTOLOGY AND PATHOGENESIS
JNA is known to spread in the submucosal plane and macroscopically this tumour 
is a soft, multilobular, rounded, circumscribed, non-encapsulated, mucosa covered 
mass (11, 12). Depending on the vascular component, the colour of the tumour 
varies from pink to pale-whitish (13), and the base of the tumour tends to be sessile 
or pedunculated (4). The mean size of JNA is ca. 4 cm, but some tumours might 
grow much larger (4, 14). Histologically, JNA consists of an abnormal vascular 
network, fi brous connective tissue stroma and stromal cells (4, 14). It has been 
shown that the larger the tumour, the greater the proportion of fi brous tissue and 
the lesser the number of vessels (15, 16). Mast cells may be seen, but otherwise no 
infl ammatory elements are present, as far as there is no surface ulceration (4, 14). 
Mitotic activity and nuclear atypia are not typical features of JNA. The vasculature 
is mostly made up by either thin-walled, slit-like (“staghorn”) or dilated vessels, 
calibres ranging from capillary to large, patulous vessels (4, 14). Muscular lining in 
the vessels walls may be totally absent, focal and pad-like, or circumferential (4, 14). 
The stroma consists of stromal cells of different shapes (plump spindle, angular, 
stellate-shaped) and varying amounts of fi ne and coarse collagen fi bers (4). Because 
12
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of the single layered intratumoural vessel walls with few or no smooth muscle cells 
and no ability to contract, together with the rigidity of the fi brous stroma, JNAs 
are highly hemorrhagic (17–19). Sarcomatous transformation, typically following 
radiation therapy, is utmost uncommon (4, 14).
Several aspects in the pathogenesis of JNA remain unsolved. Because JNA affects 
mostly adolescent males and regression of these tumours has been reported to 
happen after the full development of secondary sex characteristics, there are several 
studies aiming to elucidate the role of androgen and estrogen receptors in JNA’s 
growth and regression (9, 20–22). However, the results still seem inconsistent. 
Because of its rich vascularity, JNA has been proposed to be a hemangioma (2, 
23), a vascular malformation (17), or an incomplete regression of the fi rst brachial 
artery (2, 24). Due to the histologically benign nature of JNA, only a few studies 
exist aiming to solve the role of tumour suppressors and oncogenes in JNA. The 
expression of tumour suppressor adenomatous polyposis coli (APC) gene in JNA has 
been investigated in numerous studies, led by the discovery of increased frequency of 
JNA among patients with familial adenomatous polyposis (FAP) (25–27). The gene 
product of APC is known to regulate β-catenin, a downstream activator of the Wnt 
signalling pathway, as APC is needed for the degradation of β-catenin (25). Although 
evidence of APC gene mutations have not been found (27), activating β-catenin gene 
alterations are frequently detected in JNA (25). More interestingly, β-catenin is 
known to act as a co-activator of androgen receptors, increasing androgen sensitivity 
– which might explain the exclusive occurrence of JNA in adolescent males (28). 
The roles of tumour suppressor p53 and oncogenes C-MYC and C-FOS in JNA 
remain to be confi rmed (29, 30), while no mutations have been reported link with 
oncogenes Ki-ras, Ha-ras and Her-2/neu (30, 31). 
ROUTES OF INVASION FROM THE SITE OF ORIGIN
Starting to grow from its site of origin, the superior margin of sphenopalatine 
foramen, JNA typically fi rst reaches the nasal septum and the posterior parts of 
the nose, causing mass effect and obstruction of the airways (13). As a general view 
of JNA growth, it is believed that from here the growth proceeds and destroys the 
anterior face of the sphenoidal sinus invading the sinus. Medially the tumour grows 
towards nasal fossa and extends to the posterior parts of the middle turbinate. 
Laterally it extends towards pterygomaxullary fossa, destroying the posterior wall of 
maxillary sinus and causing the charasteristc Holman-Miller sign of anterior bowing 
of the posterior maxillar wall (4). Finally, the tumour invades the infratemporal 
fossa and the middle cranial fossa (13, 32, 33). On the whole, approximately 30% 
of all JNAs extend to the orbit and 10–20% to the cranium (34, 35).
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SYMPTOMS AND DIAGNOSIS
The classical clinical presentation of JNA is a triad of nasal obstruction, epistaxis 
and tumour mass in the nasopharynx (1, 12, 36–40). When invading the orbit, it 
can also cause proptosis and diplopia, when causing pressure to the optic nerve 
changes in visus and when reaching intracranial region, even cranial nerve palsy 
(7, 13, 41, 42). The diagnosis of JNA is based on clinical history and examination 
together with radiological fi ndings. Biopsy is contraindicated because of the risk of 
severe bleeding. Because nasal obstruction and epistaxis are common symptoms, 
one should consider also other possible diagnosis options, such as infl ammatory 
polyps, angiomatous polyps, nasopharyngeal cysts, nasopharyngeal malignancies, 
e.g., fi brosarcomas, upper maxillary malignancies, adenoid hypertrophy and 
cervical vertebra chordomas (13). The defi nite diagnosis is histologically verifi ed 
after surgery. 
As biopsies should be avoided, imaging studies are of great importance in the 
management of JNAs. These are needed preoperatively for establishing the diagnosis 
and the extent of the tumour and postoperatively for showing the extent of any 
persistent recurrent disease (5). Head and neck computed tomographic (CT) scans 
have been used since 1974 to identify typical patterns of bone erosion by JNA (43). 
For over a decade, however, also magnetic resonance imaging (MRI) has been 
used, offering improved soft tissue resolution and thus facilitating the assessment 
of spatial relationships between tumour and intracranial structures (34, 38, 44–46). 
Traditionally, CT is regarded as the most important imaging technique for JNA 
because the complexity of bony structures at skull base invaded by the tumour 
demands highly accurate bone imaging. In their review article of the evolution of 
the management of JNA, Nicolai et al. suggest the use of either multislice computed 
tomography (MSCT) or magnetic resonance imaging (MRI) and recommend the 
administration of contrast agent before use, to confi rm the clinical suspicion pattern 
of vascularisation and to estimate the extension of the lesion (2). The authors also 
state that: “Without doubt, MR better depicts cancellous bone invasion” (2), leading 
to the conclusion that as CT better depicts the damage of cortex, both techniques 
have their strengths, when concerning the invasion of skull base. 
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Figure I. Axial CT image showing tumour invading the  pterygopalatinal fossa and remodelling its bony 
walls (arrow). Coronal  CT image showing tumour extension to the Vidian canal (left arrow) and  widening 
it compared to the normal left side (right arrow). The foramen  rotundum is intact (little arrow).
Figure II. T1 weighted contrast enhanced MRI image with fat saturation, showing  the JNA tumour invading 
the pterygopalatinal fossa (upper arrow) and the  sphenoidal bone (lower arrow).
To opt for the best surgical strategy, the preoperative identifi cation of blood supply 
is essential. To evaluate the feeding vessels, angio-MRI may be helpful, though 
it is thought that mapping all the feeding vessels completely requires the use of 
digital subtraction angiography (47). Usually, JNA receives its vascular supply via 
external carotid system, more precisely from sphenopalatal artery, a branch of 
internal maxillary artery (48). When the tumour extends intracranially or into the 
skull base, the risk of additional internal carotid artery contribution is high (2). 
The use of preoperative selective angiography is supported by the fact that at the 
same time it also allows embolization of the highly vascular JNA (49). Preoperative 
selective embolization of feeding arteries has decreased intraoperative haemorrhage 
down to 30–40% of the original bleeding and made it possible to resect even the 
largest tumours (38). It is usually performed 24–48 hours prior to surgery and 
the majority of authors claim that this method signifi cantly reduces blood loss and 
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results in better surgical visualizion (6, 13, 38, 50). Regardless, Lloyd et al. state that 
embolization might lead to poor tumour removal, should there be deep invasion 
of the sphenoid (5). Arguments also exist about increased recurrence following 
embolization (39) and additionally, that embolization of the vessels from internal 
carotid artery might lead to occlusion of the ophthalmic or cerebral arteries with 
severe consequences (41, 51). However, in their review in 2012, Nicolai et al. state 
that during the last decade refi nements of techniques together with the availability 
of new materials have minimized the risk of leaving residual material, and the new 
small particles and microcatheters have enabled to avoid the risk of neurologic 
sequelae following the unintentional embolization of small vessels supplied from 
internal catorid artery (2).
A B
Figure III. JNA tumour before (A) and after (B) the embolization with polyvinyl alcohol (PVA) of external 
carotid artery via catetherization. (Courtesy of Dr. Markkola, Department of Radiology, Helsinki University 
Central Hospital).
Intratumoural injection of tissue glue, serving for a direct embolization through 
transnasal or lateral transcutanous acces was originally presented by Tranbahuy 
(52). Initially, when this procedure was presented in 1994, it did not gain much 
popularity because of the possible occurance of severe neurological complications 
(2). Recent reports with limited numbers of patients have introduced the use of a new 
embolic matrial, Onyx, with migration preventing properties and have aroused new 
interest in this procedure (53–55). Some authors suggest that whenever applicable, 
this technique should be used as the fi rst choice for reducing tumour vascularity, 
because it also prevents occlusion of intraorbital or intracranial vessels (2, 56, 57). 
A novel promising option to avoid preoperative embolization during endoscopic 
surgery is the use of new devices such as harmonic scalpel or radiofrequency coblator, 
allowing direct dissection to debulk the tumour, despite its rich vascularity (58, 59). 
16
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Whether this technique will become established in the management of JNA remains 
to be seen, but so far two reports on the use of a coblator in endoscopic surgery of 
JNA have been promising (59, 60). 
STAGING OF THE TUMOUR 
Precise staging of the tumour is important for the selection of surgical approach, for 
comparing the surgical results and for predicting tumour recurrence (61). In general, 
low stages of JNA are limited in extension, whereas advanced stages are associated 
with the involvement of skull base and with intracranial extensions (51). Based on 
advances in diagnostic and treatment techniques, numerous staging systems have 
been adopted over the years (Table I). The fi rst staging system was introduced in 
1981 by Sessions et al. (62), and after that, those poroposed by Andrews et al. (63) 
and Radkowski et al. (64) have been broadly adopted (2). In the 2000th century, 
the evolution of endoscopic surgery has led to introduction of new staging systems, 
some including also other parameters than the tumour extent and the sites of tumour 
involvement. In 2006 Önerci et al. felt that advances in imaging, embolization 
and surgical methods, especially endoscopic resection, have changed the sites, 
associated with a high risks of persistent disease and therefore suggested a new 
classifi cation for JNA (61). In their staging system they, for example, consider that 
with endoscopic surgery, ethmoid or sphenoid invasion has no effect on persistent 
disease and can be completely removed – thus tumours invading these areas should 
be classifi ed as Stage I (61). In 2008 Carrillo et al. proposed another staging system, 
which includes the tumour’s size as a new parameter which was shown to be an 
independent prognostic factor in multivariate-analysis aiming to predict the risk 
of recurrence (65). Based on a retrospective review of the outcomes of open and 
endoscopic surgery on JNA patients, in 2010, Snyderman et al. presented their 
staging system, where both endoscopic and open approaches were applicable 
and thus better predicted the immediate morbidity and tumour recurrence (51). 
This staging system, called the University of Pittsburgh Medical Center (UPCM) 
staging system for Angiofi broma, incorporates the route of invasion and residual 
vascularity following embolization, two factors that were not addressed by prior 
staging systems. According to this system, Stages I and II are considered as minimal 
stage, Stage III represents tumours that are locally advanced, e.g., with skull base 
erosion, requiring greater acces, but because of lack of residual vascularization after 
embolization, are not plagued with excessive bleeding. Stages IV and V represent 
tumours with residual vascularity after embolization and Stage V true intracranial 
tumours. Stage V is divided to medial (defi ned by extension from medial to the 
paraclival and cavernous segments of internal carotid artery), and lateral (defi ned 
by extension to the middle cranial fossa lateral to the same segments of internal 
carotid artery) divisions (51). 
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Table I. Staging systems of JNA
Staging 
system
I II III IV V
Sessions
1981
Ia:limited to 
nose and NP
Ib:extension 
into sinuses
IIa:minimal extension 
into PMF
IIb:occupation of PMF 
IIc:occupation of ITF
Extension into the 
cranium
Chandler
1984
Limited to NP Extension into nasal 
cavity or sphenoidal 
sinuses
Extension into 
antrum, ethmoidal 
sinuses, PMF, ITF, 
orbit and/or cheek
Extension into 
the cranium
Andrews
1989
Limited to 
NP. No bone 
destruction, or 
limited to SPF
Extension into PPF or 
maxillary, ethmoidal 
or sphenoidal sinuses. 
Bone destruction.
Extension into ITF 
or orbital region
IIIa:no intracranial
IIIb:extradural 
involvement
Intracranial, 
intradural 
tumour
IVa:without
IVb:with 
extension into 
cavernous 
sinus, pituitary 
or optic chiasm
Radkowski
1996
Ia:limited to 
nose or NP
Ib:extension 
into sinuses
IIa:minimal lateral 
extension into PPF
IIb:full occupation of 
PPF, with/without 
superior erosion of 
orbital bones
IIc:ITF, posterior to 
pterygoid plates
Erosion of skull 
base
IIIa:minimal 
intracranial 
extension
IIIb:extensive 
intracranial 
extension
Önerci
2006
Nose, NP, 
ethmoidal and 
sphenoidal 
sinuses or 
minimal 
extension into 
PMF
Maxillary sinus, 
full occupation of 
PMF, extension into 
anterior cranial fossa, 
limited extension 
into ITF
Extension into 
cancellous bone 
at pterygoid base 
or the body of 
the GW sphenoid, 
signiﬁ cant lateral 
extension into 
ITF or to the 
pterygoid plates 
posteriorly or 
orbital region, 
cavernous sinus 
obliteration
Intracranial 
extension 
between 
the pituitary 
gland and 
ICA, tumour 
localization 
lateral to ICA, 
middle fossa 
extension 
and extensive 
intracranial 
extension
Carrillo
2008
Nose, NP, 
maxillary 
sinuses, 
anterior 
ethmoid and 
sphenoid 
sinuses
IIa:extension into PMF 
of infratemporal fossa 
anterior to pterygoid 
plates, major 
diameter 
< 6 cm
IIb:major diameter > 
6 cm
Extension into 
infratemporal 
fossa posterior to 
pterygoid plates 
or posterior to 
ethmoid cells
Extensive skull 
base invasion 
> 2 cm of 
intracranial 
invasion
Snyderman 
2010
Nasal cavity, 
medial PPF
Paranasal sinuses, 
lateral PPF, no 
residual vascularity
Skull base 
erosion, orbit, 
infratemporal 
fossa, no residual 
vascularity
Skull base 
erosion, orbit, 
infratemporal 
fossa, residual 
vascularity
Intracranial 
extension, 
residual 
vascularity; 
M, medial 
extension, 
L, lateral 
extension
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SURGERY
Since 1955, surgical excision has been the treatment of choise for JNA (66). Other 
treatment modalities described in the literature are radiotherapy, hormone therapy, 
cryotherapy, electrocoagulation and chemotherapy (35, 49). Surgery aims at complete 
and safe resection of the tumour, with minimal morbidity and loss of blood, and 
surgical approaches most commonly used to remove JNA, have been transpalatal, 
transmaxillar (lateral rhinotomy or midfacial degloving), Le Fort 1 osteotomy, and 
infratemporal fossa approaches (12, 36, 39, 45, 63, 67, 68). Although recent reports 
recommend endoscopic surgery, the most adequate choice of treatment for the 
individual patient remains under discussion (61, 69–73). 
For more extensive tumours, midfacial degloving and lateral rhinotomy as 
transmaxillary approaches are thought to be suitable. With these approaches, 
also tumours extending into pterygopalatine and infratemporal fossae, paranasal 
sinuses, orbit, ethmoid sinus and medial part of the cavernous sinus can be surgically 
exposed. As midfacial degloving is recommended to avoid facial scars in these 
adolescent patients, yet maintaining excellent exposure to the tumour, it has gained 
popularity when compared with lateral rhinotomy (6, 74, 75). For tumours invading 
the skull base and orbital region, also the transoral Le Fort I osteotomy approach 
enables avoiding visible scars and at the same time provides broad exposure and 
great visibility of the tumour margins. However, complications of this approach 
are the possible damaging of non-erupted teeth and excessive blood loss due to 
the rupture of the palatal vessels during down-fracturing of the maxilla (67). This 
supports the invocation of preoperative embolization (5, 6, 49, 68). 
Most challenges are linked to resection of the largest tumours with intracranial 
extensions. In addition to uncontrolled haemorrhage and neurologic defi cits, 
subtotal resections and recurrences are known to be especially common among these 
high-stage tumours (36, 68, 76, 77). Various craniotomy modifi cations have been 
used, entailing also a number of possible complications. The use of infratemporal 
approach may result in conductive hearing loss on the operated side as well as in 
the sacrifi ce of the mandibular division of the trigeminal nerve (63, 78). Further, 
because JNA patients are all adolescent, a risk of facial growth retardation is always 
present when using invasive approaches. 
Initially, the endoscopic approach was recommended exclusively for tumours 
limited to the nasopharynx, the nasal cavity, ethmoid and sphenoid sinuses and 
with only slight extensions to the pretygopalatine fossa. Recently, selected cases of 
tumours expanding to the pterygopalatal fossa, infratemporal fossa and even with 
limited intracranial involvement have been successfully managed endoscopically (61, 
79, 80). However, consensus remains that endoscopic approach has its limitations 
and is not recommended for tumours with extensive intracranial extensions, or 
extensions laterally to the cavernous sinus (69, 73). In addition, external approach 
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is preferred for tumours with extensive blood supply from internal carotid artery 
(73).Yet, surgeon’s experience in the area of endoscopic surgery, remains critical. 
Advantages of the endoscopic approach are enhanced surgical visualization 
with magnifi ed and multiangled views, thought to prevent overlooking of tumour 
remnants, along with the avoidance of facial scars and bone disruption. Endoscopic 
surgery is associated with lower morbidity, low rate of complications, and shorter 
period of hospitalization (11, 70, 71, 81, 82). When compared with traditional 
surgical approaches, the risk of recurrence is reported to be lower (35). In addition, 
combining the endoscopic technique with open approach allows delicate inspection 
of the surgical cavity and enables further resection, if necessary. Herman et al. have 
showed this combination to decrease the likelihood of tumour recurrence (83). 
Many authors have described the importance of exploring the basis of the sphenoid 
to remove all tumours invading the cancellous bone at the skull base, which might 
be better achieved with endoscopic resection (5, 74, 84). Based on their results of 
the spenoidal invasion and recurrence, Howard et al. present a hypothesis that this 
invasion could be the major cause for incomplete tumour excision and thus more 
radical surgery would reduce the recurrence rate (74). They mention, however, 
that in their series of 72 patients, the verifi cation of this hypothesis is impossible, 
because several confusing factors, such as the number of surgerons involved in the 
operation and different surgical procedures (74). This is very important observation 
and should be taken into account in relation to all results with factors affecting the 
outcome of JNA. A high degree of skill is mandatory for the operating surgeon. 
Limitations of the endoscopic approach are loss of two-handed dissection, and 
weak visibility in the case of bleeding. Based on this, most authors agree, that 
preoperative embolization of the feeding vessels is essential for haemostasis and 
visualization of the surgical fi eld (82, 85). Other, new treatment modalities have 
been developed during the last decade. The use of imaging guided navigation in 
JNA operations for safety reasons (57, 75, 86), Cavitron ultrasonic surgical aspirator 
(CUSA), a useful dissection system with obvious advantages allowing more accurate 
endoscopic removal of the tumour and peroperative use of intratumoural injections 
of cyanoacrylate glue are suggested to help in the dissection of JNA (56). The use of 
transoral robotic surgery possibly combined with transnasal endoscopic surgery has 
been reported to be useful when resecting recurrences of nasopharyngeal carcinoma 
(87, 88). As the equipment for transoral robotic surgery develops, this technique 
could be a new promising treatment option for JNA tumours as well. 
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RADIOTHERAPY
Although surgery is considered as the treatment of choise for JNA, the potential 
morbidity and mortality associated with operating intracranial tumours has motivated 
others to investigate the role of radiotherapy for these patients (9). At present, 
external radiation therapy, either conventional, intensity-modulated or Gamma 
knife is generally used for patients with unresectable tumour or for those whose 
clinical condition prevents surgery (57, 89–91). It has been shown that radiotherapy 
and surgery are evenly effective in the treatment of JNA (77). However, the well 
known long-term complications of radiotherapy, such as secondary malignancies, 
endocrine hypofunction, cataract and glaucoma, must be taken into account and 
compared with the risks of intracranial surgery (92).
FOLLOW UP
Because of the submucosal growth of JNA, MRI and MSCT are superior to 
endoscopic examination to identify any residual or recurrence (2). Due to the 
infl ammatory changes usually seen 3–4 months after surgery, differentation 
between JNA and active scar tissue might be highly challenging (2, 93). This is 
why a number of authors have recommended postoperative MRI to be performed 
after the removal of nasal packaging until 72 hours for early identifi cation of any 
questionable residual disease (2, 93). Other authors state that follow-up imaging 
should not be performed earlier than at 6 weeks, as an early CT or MRI scan can 
give a false impression of a residual tumour due to various postoperative artefacts 
(84). In their review published in 2012, Nicolai et al. recommend that regardless 
of the follow-up technique selected, it should be performed every 6–8 months for 
at least 3 years after surgery (2).
RECURRENCES
Recurrences are common in the management of JNA, the majority of which occurs 
during the fi rst year after surgery (38). JNA is a unifocal benign disease and thus 
recurrence is often thought to represent a residual tumour due to incomplete 
resection. In 2007, Tyagi et al. showed that an evident residual tumour is an 
independent risk factor for recurrence (84). It has been proposed and later accepted 
by others that high rates of recurrence might be consequent on failure to recognize 
the skull base erosion (38, 57, 83). Yet, in their study of chromosomal alterations in 
JNA, Heinrich et al. reported few or no alterations in recurrent tumours, compared 
with numerous DNA gains in primary tumours (94). They conclude that this supports 
a concept of newly formed tumours, in that the same patterns of chromosomal 
aberrations would be expected in recurrence from residual tumour cells (94).
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Recurrence rates for JNA vary from up to 50% reported in the 1980s and 1990s 
(1, 5) to 13.5% in the study of Danesi (95), when comtemplating open surgical 
approaches and to less than 10% when analyzing a series of endoscopically treated 
patients (73, 74, 96). In addition to the explicit tumour residual, factors associated 
with recurrence have been reported to be patients who are young at the time of the 
diagnosis, the size and stage of the tumour (97) and its vessel density (98). Lund 
et al. have suggested that JNAs undergo a cycle of aggressive growth followed in 
some cases by regression (99). Thus, the date when surgery is performed may be 
important in determing the so-called recurrence of the tumour, when the remaining 
part of the tumour attains new blood supply and undergoes regrowth of variable 
speed – depending on the point in the cycle the tumour is facing (99, 100).
INVOLUTION OF JNA
Despite the fact that tumour recurrence almost certainly represents tumour 
persistence, there are reports of incompletely resected tumours that have not 
progressed during a reasonable follow-up time, and involution of JNA tumour 
remnants has been suggested to happen infrequently (84, 101, 102). Thus, residual 
disease should not always be considered as a recurrence, because tumour remnants 
can be found by postoperative imagining in patients who remain symptom-free 
and therefore one must differentiate true new tumour growth from symptomless, 
non-growing tumour residual (57, 76, 79, 101). Factors indicating the evolution of 
tumour remnants remain unsolved, although it has been proposed that in young 
patients remnants might be expected to keep growing, while in older patients, they 
may disappear, due to the putatively hormonally dependent pathogenesis on JNA 
(2, 83). The idea of JNA involuting with age is supported by histological fi ndings, 
as individual tumours tend to express an increase in fi brous elements with time 
(103). Spontaneous involution of JNA, without any treatment attempts, has been 
reported in some patients (102, 104, 105), but the background of this phenomenon 
remains to be elucidated. 
2.2 PROTEINS KNOWN TO ACT AS TUMOUR MARKERS FOR  
 CELL PROLIFERATION AND ANGIOGENESIS 
C-KIT
C-KIT, also known as CD117, is a type III receptor tyrosine kinase that belongs to 
the family of platelet derived growth factor receptors (PDGFRs). Activated C-KIT 
activates numerous transcription factors regulating apoptosis, cell differentiation, 
proliferation, chemotaxis, and cell adhesion (106–109). C-KIT is required for 
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regulating the normal development of stem cells, germ cells, melanocytes, and 
peristalsis regulating Cajal cells in the gastrointestinal tract (107, 110–112). 
Expression of C-KIT has been found in many malignant nonlymphoid solid tumours 
(113–115), suggesting that C-KIT might participate in growth signalling in these 
tumours (116, 117). 
Interestingly, C-KIT expression has also been found in the vasculature of many 
types of malignant tumours (118). However, in some tumours, when compared to 
corresponding normal tissue, there has been loss of C-KIT expression (116, 117). 
Thus, it has been proposed that C-KIT with its ligand might have mitogenic effects in 
some cell lines and regulation of cell differentation and morphogenesis in others.
C-KIT expression in benign tumours is less studied, and it appears to be 
mostly absent in benign neoplasms (119). Yet, in salivary gland adenomas and 
angiomyofi broblastomas, moderate to strong immunopositivity for C-KIT has been 
found (113, 118, 120). In the case of JNA, alternative results exist concerning C-KIT 
expression. In a series of 12 JNA samples, Zhang et al. reported strong C-KIT 
expression in stromal cells only and suggested that C-KIT might have a role in the 
progression of JNA (121). On the other hand, Pauli et al. evaluated stromal cells in 
52 samples of JNA and found all of them to be C-KIT negative (122).
C-MYC
C-MYC is a proto-oncogene, taking part in cell proliferation, differentiation and 
apoptosis by activating other genes (123–126). It is also known to have potent 
angiogenic activity (126, 127). C-MYC overexpression is associated with several 
malignant neoplasms, such as breast and colon carcinomas, osteosarcomas and 
melanomas (124, 128, 129) and C-MYC gene amplifi cation is linked with advanced 
stage of the disease (126–128). Only a few studies have tried to demonstrate C-MYC 
expression in benign tumours, and the results have been negative (130, 131).
In their Northern blot study, Nagai et al. studied the expression of C-MYC mRNA 
in 25 cases of JNA but found no difference when compared to normal tissue (29). 
Later, in three advanced cases of JNA, Schick et al. succeeded to demonstrate gains of 
C-MYC, associated with increased mRNA and protein expression levels, suggesting 
a probable role for C-MYC in the progression of JNA (129). The observation that 
C-MYC participates in angiogenesis by inducing fi broblasts to build up an immature 
vascular network of leaky, unstable kind of blood vessels, (132) is of great interest, 
because malformed, slit-like vessels are known to be a part of JNA histological 
architecture (16).
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BMI-1
Polycomb group proteins (PcGs) are epigenetic gene silencing proteins that 
participate in embryonic development and oncogenesis (133–136). As a collaborator 
of C-MYC in oncogenesis, BMI-1 (B lymphoma Mo-MLV insertion region 1 homolog) 
was the fi rst mammalian PcG gene identifi ed in 1991 (137). By methylating and 
acetylating the chromatin and histones, BMI-1 maintains the transcriptionally 
repressed state of many genes (138), and thus also the primitive state of tissue stem 
cells, enabling stem cell self-renewal (134, 139–141). Because BMI-1 regulates genes 
involved in cell cycle and cell differentiation, it can function as a potent oncogene 
(142–144). BMI-1 overexpression in various malignant tumours correlates with 
poor prognosis, while in other tumours, lack of BMI-1 expression has been found 
to correlate with a high recurrence rate (143, 145–147).
GLUT-1
Glucose transporter 1 (GLUT-1) is an erythrocyte type glucose transport protein 
participating in cellular response to hypoxia (148). It is expressed in high levels in 
e.g., erythrocytes and placental trofoblasts, whereas in most tissues it is constitutively 
expressed at low levels (149–152). Presumably due to enhanced glycolytic metabolism, 
upregulation of GLUT-1 expression has also been shown in many carcinomas (148). 
Of mesenchymal tumours, GLUT-1 is constantly expressed in juvenile hemangiomas 
and hence it is used in the differential diagnosis of vascular malformations (153, 154). 
Other tumours of mesenchymal lineages, e.g., chordomas, epithelioid sarcomas, 
gastrointestinal stromal tumours, adipocytic tumours and myogenous tumours have 
also been shown to express GLUT-1 and the observation that GLUT-1 expression in 
sarcomas was assosiated with necrosis, whereas low-grade mesenchymal tumours 
were GLUT-1 negative, proposes that its overexpression might be a refl ection of 
hypoxia (148, 155). 
TENASCIN-C
Besides of the two major components of extracellular matrix (ECM), 
glycosaminoglycans and fi brous proteins, this meshwork also includes numerous 
fi ber-assosiated proteins, such as tenascins. Structurally similar proteins, tenascin-C 
(TNC), -W, -R, and –X, have different patterns of expression in different tissues, 
leading to the idea of their own solute functions (156–158). In developing epithelia, 
TNC is expressed in the surrounding mesenchyme of different organ systems. In 
adults, however, the expression of tenascins becomes more restricted. Tenascins 
are upregulated in infl ammation and tumourigenesis – in cancers, TNC can be 
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secreted either by tumour cells themselves or more commonly, by fi broblasts in 
the surrounding stroma. Its contribution to tumour development is thought to be 
a direct stimulation of tumour cells to proliferate or promotion of angiogenesis via 
its impact on endothelium (159–163). 
SYNDECANS
Syndecans are membrane proteoglycans consisting of a core protein and heparan 
sulphate chains and constitute the major class of heparan sulphate proteoglycans 
in vasculature. Their expression varies both temporally and spatially, but it is 
acknowledged, that almost all nucleated cells express at least one member of the 
syndecan family (164–166).
Syndecan-1 is the most studied of the four mammalian syndecans. In adult 
tissues, it is mostly expressed by epithelial cells, but during development also 
in both epithelial and mesenchymal cells (167, 168). Syndecan-2 is expressed in 
mesenchymal, neuronal and muscle cells and is the major syndecan in microvascular 
endothelial cells (169, 170). Syndecans interact with various ligands through their 
heparan sulphate chains and are known to be involved in cell-cell and cell-matrix 
interactions, cell proliferation, migration and differentiation. Although traditionally 
classifi ed as adhesion molecules, syndecans have been shown to have an essential 
role in vascular development and repair by binding and tranducing the signals 
of growth factors, e.g., of vascular endothelial growth factor (VEGF). Syndecan-2 
plays an essential role in angiogenesis by stimulating endothelial cells to proliferate, 
migrate and generate new tubular structures. Its downregulation is known to reduce 
the spreading and adhesion of endothelial cells, enchance their migration, and 
impair the formation of normal, capillary-like structures (169, 170).
SYK
Over 500 kinases are encoded by the human genome and the interest in investigating 
these proteins is partly explained by the development of kinase inhibitors for 
oncological targets. Spleen tyrosine kinase SYK is a non-receptor tyrosine kinase 
originally cloned from porcine spleen (171, 172). Activated SYK conducts numerous 
cellular responses, such as cell proliferation, differentiation, survival and phagosytosis 
(171, 172). Although, initially SYK signalling pathway was thought to be restricted 
only to hematopoietic cell responses, in particular to immunoreceptor signalling 
events, recent works have demonstrated that SYK exhibits a widespread expression 
pattern in various nonhematopoietic cells. It appears to have a functionally centered 
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role on, e.g., nasal fi broblasts, vascular endothelial cells, epithelial cells, breast tissue, 
neuronal cells and hepatocytes (173). 
SYK has been linked to the development of haematological and non-
haematological malignancies and is required for the oncogenic acitivity of several 
viruses, such as Epstein-Barr virus (174–177). In these virus-induced tumours SYK 
has a putative tumour-promoting role, whereas in nonhaematopoietic tumours it 
has been proposed to suppress tumour growth (172). This was fi rst suggested by 
Cooper et al. in 2000, as in their material, SYK was expressed in normal breast 
tissue, benign breast lesions and low-tumourigenic breast cancer cell lines, but in 
invasive breast cancer SYK mRNA and protein were low or undetectable (171). 
Transfection of SYK in these tumours suppressed tumour growth and metastasis 
formation (171). Later this study has been substantiated and complemented by 
various clinical investigations (178–181). However, in e.g., chronic leukemia, gastric 
cancer, and oral squamous cell cancer high SYK expression correlates with tumour 
progression and has prognostic value, thus SYK acting as an oncogene (182). 
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3 AIMS OF THE STUDY
The main goal of this study was to elucidate factors determining the outcome of 
juvenile nasopharyngeal angiofi broma, JNA. 
For this purpose we
 investigated the various surgical techniques used to resect JNA • 
during the past 40 years at our Institution, in order to settle 
their effect on the outcome and possible tumour recurrence. 
In addition, other potential clinical factors influencing the 
tumours’ tendency to recur in this series were recorded (Study I);
  studied the expression of several proteins known to • 
participate in tumour- and angiogenesis, to find out 
if they were predictive also in JNA (Study II and III);
 combined the copy number and gene expression data of two • 
phenotypically different JNA tumours to seek for processes putatively 
determining their growth pattern (Study IV).
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4  MATERIALS AND METHODS
4.1 PATIENT MATERIAL
4.11 RETROSPECTIVE MATERIAL 
The clinicopathological data of all patients diagnosed for a histologically verifi ed JNA 
during the 42-year period between January 1, 1970 and December 31, 2011 at the 
Helsinki University Central Hospital (HUCH), Helsinki, Finland were retrospectively 
reviewed. The health-care district included in this study represents almost one third 
of the whole country, including approximately 1.5 million inhabitants. To identify 
the patients, hospital surgical and discharge registries as well as the database of 
the Department of Pathology, HUCH, were used. A total of 27 male patients were 
included, the mean age being 17 years. Details on the patients’ age, sex, presenting 
signs and symptoms, the duration of symptoms, date of diagnosis, tumour site, 
imaging, whether preoperative embolization was performed, histopathology of the 
neoplasm, stage of the tumour, feeding arteries, treatment modality and the surgical 
approach performed, rate of recurrence, date of last follow up, and status at last 
follow up were collected from hospital records. All patients had a minimum follow 
up of seven months. 
4.12  PROSPECTIVE MATERIAL (STUDY IV)
Fresh tissue samples were prospectively collected from two patients who underwent 
surgery at our Institution between 2008 and 2011. The fi rst patient (HS as High 
Stage) was 15 years old at the time of diagnosis and had a tumour extending 
to pterygopalatinal fossa, sphenoid, ethmoid, and/or maxillary sinuses, orbit 
and middle cranial fossa, representing Stage IIIa according to Andrew’s staging 
system. After the fi rst operation this patient got a recurrent disease and hade to 
face two re-operations. Additionally, radiotherapy and antiangiogenic therapy were 
administered, due to persistent intracranial growth. The other patient (LS as Low 
Stage) had a small tumour (3 cm in diameter), limited only to the nasopharynx. 
After endoscopic removal, this patient had no evidence of disease. These two 
phenotypically different JNA tumours were sampled and snap-frozen in liquid 
nitrogen within 20 minutes of devascularisation and stored at -80 C to be used 
for microarray analysis.
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4.2 HISTOLOGY OF THE TUMOURS AND 
 IMMUNOHISTOCHEMISTRY (STUDY II, III AND IV)
Formalin fi xed and paraffi n-embebbed samples of JNA tumours from the fi les 
of the Department of Pathology, University of Helsinki were used. The diagnoses 
were histologically confi rmed by experienced pathologists (PH and JH). Samples 
were scored for cell number per mm2 and from these the mean cell density was 
calculated. For vessel density analysis, vessels marked by CD31 were counted per 
mm2 and the mean counts were calculated. All CD31 positive vessels were included 
in this counting, and at this point, no separation between smaller and larger vessels 
was made.
For immunohistochemical staining, formalin fi xed and paraffi n-embebbed 
samples were cut into 4 μm micrometer-thick sections deparaffi nized in xylene 
and rehydrated through a graded alcohol series. For antigen retrieval, slides were 
treated in a PT-module (LabVision UK Ltd, UK) with Tris-HCl buffer (pH 8.5), Tris-
EDTA for 20 minutes at +98°C, or with Trypsin (1g/200 ml PBS) for 30 minutes 
at +37°C. Immunohistochemical stainings were performed in Autostainer 480 
(LabVision) using Dako REAL EnVision Detection System, Peroxidase/DAB+, 
Rabbit/Mouse (Dako, Glostrup, Denmark). The slides were treated with 0.3% 
Dako REAL Peroxidase-Blocking Solution (Dako) to block endogenous peroxidase 
activity followed by primary antibody incubation with specifi c antibodies for each 
antigen (Table II) for one hour, followed by a 30-min incubation with Dako 
REAL EnVision/HRP detection system, Rabbit/Mouse (ENV) reagent (Dako). 
The slides were fi nally visualized by Dako REAL DAB+ Chromogen (Dako) for 
10 min. PBS-0.04%-Tween20 washing was accomplished between each step. 
Slides were counterstained with Meyer’s hematoxylin and mounted in mounting 
medium (Aquamount, BDH, Poole, UK). Mouse monoclonal antibody for CD31 
(clone JC70A, Dako) mouse monoclonal antibody for SYK (clone 4D10.1, Abcam, 
Cambridge, UK), mouse monoclonal antibody for GLUT-1 (clone SPM498, Thermo 
scientifi c, Cheshire, UK), monoclonal antibody for tenascin –C (clone DB7 (IgG2a), 
Biohit, Helsinki, Finland), mouse anti-human syndecan-1 (clone β-B4, Serotec, 
Hämeenlinna, Finland), mouse monoclonal C-MYC (clone 9E10, Santa Cruz, CA), 
mouse monoclonal BMI-1 (ab 14389, Abcam), or polyclonal C-KIT (A4502, Dako) 
and rabbit anti-syndecan-2 (clone ZMD.308, Invitrogen, Nuppulinna, Finland) were 
used for one hour, followed by a 30-min incubation with Dako REAL EnVision/
HRP detection system, Rabbit/Mouse (ENV) reagent. 
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Table II. Antibodies used in immunohistochemistry (Study II, III and IV)
Antibody Dilution Pre-treatment Study
CD31 1:20 Tris-HCl I, II, IV
C-KIT 1:400 Tris-HCl II
C-MYC 1:400 Tris-EDTA II
BMI-1 1:300 Tris-EDTA III
GLUT-1 1:1000 Trypsin III
TNC 1:50 Tris-EDTA III
Syndecan 1 1:2000 Tris-EDTA III
Syndecan 2 1:250 Tris-EDTA III
SYK 1:2000 Tris-EDTA IV
4.3 SCORING OF IMMUNOSTAININGS (STUDY II, III AND IV)
All stained samples were evaluated (N= 26 for study II and N=27 for studies III 
and IV) except for C-MYC, BMI-1, TNC (N=25) and syndecan 1 (N=21) because of 
the insuffi ciency of samples.
Independently and without knowledge of the clinical data, two assessors (JH 
and PH or JH and SR) scored the immunostainings by evaluating the percentage of 
positive tumour cells. The average staining was estimated by evaluating the whole 
tissue slide. No positivity was scored as 0, up to 30% positive cells as 1 (very low), 
30–50% as 2 (low), 50–80 % as 3 (high) and over 80% as 4 (very high). This 
scoring system has been modifi ed from Häyry et al. (183). In the case of GLUT-1 
and syndecan-2, however, the expression was scored positive or negative. Stroma, 
large and slit-like vessels were scored separately for these samples.
4.4 SAMPLE PREPARATION FOR GENE EXPRESSION AND   
 COMPARATIVE GENOMIC HYBRIDIZATION MICROARRAYS  
 (STUDY IV)
To extract total RNA from two JNA tissue samples, Qiagen RNeasy mini kit (Qiagen) 
was used according to the Manufacturer’s instructions. The integrity of RNA was 
measured using Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA). Two-
hundred and fi fty nanograms of total RNA was used for labelling and 12.5 μg of 
fragmented aRNA was hybridized on microarrays according to the manufacturer’s 
instructions (Affymetrix, Santa Clara, CA). For DNA copy number analysis, DNA was 
extracted using DNeasy Blood & Tissue Kit (Qiagen). Two micrograms of genomic 
DNA was used for array hybridizations according to the manufacturer’s instructions 
(Agilent Technologies).
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4.5 GENE EXPRESSION DATA ANALYSIS (STUDY IV)
To study the gene expression profi les of JNA tissue samples, Affymetrix GeneChip® 
Human Genome U133 Plus 2.0 (Affymetrix, Santa Clara, CA) gene expression arrays 
were used. GeneChip signal intensity data were processed with robust multiarray 
analysis (184) using re-mapped gene annotations from the Brainarray Custom CDF 
fi les (HGU133Plus2_Hs_ENSG, v.14.1.0, http://brainarray.mbni.med.umich.edu/
Brainarray/) (185). In contrast to the ordinary annotation fi les with 54,675 probe 
sets, this custom chip description fi le has 18,982 probe sets, corresponding to 
the newest set of EnsEMBL genes. The signifi cance of differential expression was 
assessed using the empirical Bayes moderated paired t-statistics followed by p-value 
adjustment with the Storey’s approach (186). Arrays were quality weighted before 
statistical testing (187). Genes with p-values ≤ 0.05 were considered as signifi cantly 
differentially expressed. All methods used are implemented in the simpleaffy, limma 
and qvalue packages of the Bioconductor project (186, 188, 189).
4.6 COMPARATIVE GENOMIC HYBRIDIZATION ANALYSIS   
 (STUDY IV)
Copy number variations in JNA tissue samples were studied using Agilent Human 
Genome CGH 244A Oligo Microarray (Agilent Technologies). Array intensity data 
were processed with Agilent Feature Extraction tool (Agilent Technologies). Probes 
associated with genomic coordinates according to the Manufacturer’s annotation 
were selected and coordinates (NCBI36/hg18) converted to the newest genome 
build (GRCh37/hg19) using LiftOver. For copy number variation (CNV) status of 
genes, averages were taken over probes locating within the start and end coordinate 
of EnsEMBL gene models. Similar to gene expression data, CNV status is given as 
log2 transformed values.
4.7 GENE ENRICHMENT SET ANALYSIS (STUDY IV)
To describe the gene and the gene product attributes of any organism, a controlled 
vocabulary is provided by the gene ontology categories (190). The GOrilla Gene 
Enrichment Analysis and Visualization Tool (191) was used to discover the gene 
ontology term enriched at either end of a gene list sorted according to the moderated 
t-test score calculated using limma. All three gene ontology categories were tested. 
Functional groups enriched among statistically signifi cantly differentially expressed 
genes were tested with DAVID (192).
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4.8 PROTEIN-PROTEIN INTERACTION NETWORKS (STUDY IV)
For integrated protein-protein interaction data, we used Web-based protein 
interaction network analysis platform (PINA) (193) providing data from six 
databases. This was exploited to identify the interactor proteins of investigated 
proteins.
4.9 STATISTICAL ANALYSIS (STUDY II, III AND IV)
For cross-tabulation and analysis of categorical variables Fisher’s exact test or 
Spearmann correlation were used. All p-values are two-sided and values less than 
0.05 were considered signifi cant. For survival analysis, an event was defi ned as 
the discovery of recurrence of the tumour. Follow-up time was calculated from the 
fi rst operation until the event. Patients with no evidence of recurrence or patients 
deceased from non-tumour-related cause (N=1) were censored on the last date 
of follow up. To compare the outcome between patient categories, we generated 
Kaplan-Meier curves and applied log-rank test. SPSS version 15.0 software (SPSS, 
IL) was used for statistical analyses.
4.10 ETHICAL CONSIDERATIONS (STUDY I, II, III AND IV)
The project was approved by the Research Ethics Committee of the Helsinki 
University Central Hospital, Hospital District of Helsinki and Uusimaa (diary 
number 114/12/03/04/2008), and all work was done in accordance with the 
Helsinki declaration.
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5 Results
5 RESULTS
5.1 PATIENTS (STUDY I, II, III AND IV)
The series consisted of 27 male patients, one of whom was diagnosed after submitting 
studies I and II. Median age at presentation of symptoms was 17 years, ranging 
from 11 to 33 years. All tumours were located in the nasopharynx and depending on 
tumour size and growth pattern, had extension to the adjacent structures. Thirteen 
cases (48%) showed extension to the sphenoid sinuses, eight cases (30%) to the 
ethmoid sinuses, seven cases (26%) to the pterygopalatine fossa, fi ve cases (19%) 
to the maxillary sinuses and two cases (7%) to the orbital, infratemoral and middle 
cranial fossae. 
Depending on their location and growth pattern, tumours were classifi ed 
according to Andrews staging (Table I). Seven tumours (26%) were limited to the 
nasal cavity without bone destruction, representing Stage I. 
All patients were primarily treated with surgery. Surgical approaches were typically 
chosen by the extent of the tumour and included transpalatal, transmaxillary (either 
sublabial degloving or lateral rhinotomy approach), endoscopic, and craniotomy 
(Table III). A combination of two surgical approaches was used to treat fi ve patients 
(19%). Two patients with Stage I and II tumours were treated endoscopically. The 
fi rst endoscopic surgery at our Institution was performed in 1998. 
The recurrence rate was 37% (N=10) and recurrence was discovered on the average 
at 10.5 months (range 3–19 months) after the fi rst operation. In all cases, recurrence 
was removed surgically, and exept for two patients, this was done by combining 
two surgical approaches. No recurrences were treated endoscopically. Recurrence 
was still discovered, on the average eight months after the second operation (range 
5–12 months) in six patients (22% of patients, 60% of all recurrences). Two patients 
(7%/20%) had to be operated four times, and both of these patients were free of 
disease after 108 and 177 months of follow up, repectively. At the last follow-up visit, 
half (N=5) of the total of 10 patients with a recurrence, had no evidence of disease 
while the rest were alive with disease and under follow up. One of our patients 
has been additionally treated with stereotactic radiotherapy and antiangiogenetic 
(celecoxib, thalidomide, etoposide) therapy after three operations. Altogether two 
patients (7%) have received antiangiogenetic therapy in this series. 
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Table III. Management of JNAs in this series
SURGICAL APPROACH
Transpalatal 14 (52%)
Transmaxillar 2 (7%)
Endoscopic 3 (11%)
Craniotomy 2 (7%)
Combinded 6 (22%)
SURGERY FOR RESIDUAL DISEASE
Once 10 (37%)
More than once 6 (22%)
STATUS AT LAST FOLLOW UP
No evidence of disease 21 (78%)
Alive with minimum residual disease under surveillance 6 (22%)
One patient (4%) received postoperative radiotherapy and two patients (7%) were additionally 
treated with antiangiogenic agents.
Except for one 24 years old patient, patients with a recurrence were between 10 
and 17 years old at the time of diagnosis. All patients who had more than two 
reoperations were under the age of 15 at the time of diagnosis. Among the nine 
patients older than 17 years at the time of diagnosis, only one had a recurrence. A 
correlation was found between the number of needed reoperations and the surgical 
approach used, as the tumours removed transpalatally had higher risk of multiple 
recurrences when compared to other approaches (Fisher’s exact test p=0.004) 
The median follow-up time was 106 months (range 7–360 months). All patients 
remained either with no evidence of disease (N=20, 74%) or were alive with minimal 
signs of persistent disease (N=6, 22%) at the last follow-up visit, except for one 
patient, who perished for another reason during the follow up. There was no evidence 
of malignant transformation in any patient.
5.2 HISTOLOGY OF THE JNA SAMPLES (STUDY II) 
Great variation in cell densities and the amount of fi brous stroma was detected 
between different JNA samples. The vascular architecture of the samples was studied 
with endothelial marker CD31 and it showed vessels of different numbers, sizes and 
shapes (Figure IV). The vascular density of the tumour was found to have a signifi cant 
correlation (Fiher’s exact p=0,040) with the tumour’s tendency to recur. 
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Figure IV. JNA tissue with high (left) and low (right) vessel density marked with endothelial marker 
CD31.
5.3 PROTEIN EXPRESSION (STUDY II AND III)
C-KIT expression was frequently present both in stromal (25/ 26) and endothelial 
cells (24/26) in the current JNA tissue samples. Because of the notable variety 
in vessel diameter and shape, C-KIT expression in endothelial cells was studied 
separately in large vessels and slit-like vessels without muscular lining. In slit-like 
vessels, C-KIT positivity was detected in 23 samples (23/26), whereas in large vessels 
in only 14 samples (14/26). When present, the intensity of C-KIT expression ranged 
from very low to moderate.
Nuclear C-MYC positivity was detected in stromal cells of the majority of JNA 
tissue samples (21/25). Expression intensity ranged from very low to high. 
All JNA tissue samples analyzed (25/25) showed nuclear BMI-1 protein 
expression in stromal cells. BMI-1 expression levels varied from very low to high.
GLUT-1 expression was occasionally present in both stromal and endothelial 
cells. Also GLUT-1 was analyzed separately in slit-like and large vessels but appeared 
to be approximately equally prevalent in both groups (7/27 in slit-like vessels, 8/27 
in large vessels) as well as in stromal cells (6/27).
TNC expression was detected in stromal cells only, in most of the studied JNA 
cases (23/25). Its expression pattern was patchy and surrounded vessels. Expression 
levels ranged from very low to high.
Syndecan-1 was expressed in stromal cells only, and all samples studied (21/21) 
were immunopositive. The expression was perivascular and the level of syndecan-1 
expression ranged from very low to high, being low in most cases. Syndecan-2 was 
expressed in both endothelial and stromal cells of JNA samples. Also syndecan-2 
immunopositivity was analyzed separately in slit-like and large vessels, and was 
most prevalent in slit-like vessels (21/27). Only one sample was totally negative 
for syndecan-2.
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Cytoplasmic SYK protein expression was detected in stromal cells of all JNA 
tissue samples analysed (27/27). The frequency of SYK expression levels varied 
from very low to high. 
5.4 CORRELATIONS WITH CLINOCOPATHOLOGICAL FACTORS  
 (STUDY II AND III)
The protein expression levels of C-KIT, C-MYC and BMI- 1, GLUT-1, TNC, 
syndecan-1, syndecan-2 and SYK were compared with each other, cell and vessel 
density, tumour stage, and patient age. A signifi cant correlation between endothelial 
expression of C-KIT and cell density was found (Spearman correlation p=0.009). 
Endothelial C-KIT protein expression was also found to correlate with stromal 
C-MYC protein expression (Fisher’s exact p=0.006), while no correlation between 
the C-MYC protein expression and cellular or vascular density was found. No 
correlation between the immunoexpression of BMI-1 and other parameters studied 
was found.
TNC seemed to correlate with many other factors, including vessel density 
(Fisher’s exact p=0.01, Spearman correlation p=0.004), tumour stage using 
Andrew’s staging system (Spearman correlation p=0.001), endothelial C-KIT 
expression (Spearman correlation p=0.027) and stromal GLUT-1 (Fisher’s exact 
p=0.002, Spearman correlation p=0.001). Also, the expression of endothelial 
GLUT-1, when present, had a signifi cant correlation with tumour stage (Fisher’s 
exact p=0.011). Syndecan-1 and syndecan-2 had no correlations with any of the 
above-mentioned factors. SYK had a signifi cant correlation with lower tumour stage 
(Fisher’s exact p=0.048). 
5.5 SURVIVAL ANALYSIS (STUDY I AND III)
Time from the primary operation to the time point of tumour recurrence was 
estimated with the Kaplan-Meier method related to C-KIT, C-MYC, BMI-1, GLUT-1, 
TNC, syndecan-1, syndecan-2 and SYK expression, to cell and vessel densities and 
to tumour stage and patients’ age at the time of the diagnosis. Lack of syndecan-2 
expression in slit-like vessels seen in six patients, was found to be associated with 
poorer recurrence-free survival (log-rank test p=0.022). When syndecan-2 was 
expressed in slit-like vessels, the median survival time was 48 months, whereas in 
negative cases it was only 9 months. Also patients’ age under 16 years at the time 
of the diagnosis was found to be associated with poor recurrence-free survival (log-
rank test p=0.013) (Figure V).
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Figure V. Young age aff ecting the recurrence-free survival of JNA patients.
5.6 GENE COPY NUMBER ABERRATIONS (STUDY IV)
The gene copy numbers from the low stage (LS) and high stage (HS) specimens 
were compared to gender-matched DNA obtained from white blood cells of healthy 
individuals (Promega, Wisconsin, WI). Then the copy number gains and losses were 
compared between the two different samples. The log2 cut-off values for gains and 
losses were 1 and -1, respectively, indicating a two-fold difference in copy number. 
Between the LS and HS samples and their corresponding controls, 46 genes showed 
at least a two-fold copy number difference. Compared with each other, the copy 
number change between these two samples was at least two-fold in 11 genes. 
5.7 GENE EXPRESSION LEVELS (STUDY IV)
Between LS and HS, at least two-fold change in the gene expression levels was 
discovered in 1383 transcripts, of which in 1245 cases the q-value was <0.05. The 
level was higher in LS in 773 transcripts and in HS in 610 transcripts. Expression 
level changes related to copy number changes were seen in three genes. 
37
5.8 GENE ONTOLOGY (STUDY IV)
Assessment with GOrilla revealed some strongly enriched categories that where 
different in LS and HS tumours. Genes overexpressed in the LS tumour were 
commonly associated with biological functions linked to the tumour organization, 
like development of the vasculature and epithelium, cell adhesion and collagen 
catabolic functions, and also hypoxia. As in the HS tumour with recurrences, the 
upregulated genes were enriched into categories like signal transduction activity, 
including positive regulation of phosphorylation, tumour necrosis factor (TNF) 
production and Wnt-activated receptor activity. 
One of the genes with an over two-fold change in expression levels between LS 
and HS was tyrosine kinase SYK, known to participate in tumourigenesis of various 
other tumours. This protein was decided to be studied further, both computationally 
as well with immunohistochemical analyses. To identify proteins interacting with 
SYK, we used protein interaction database tool, PINA (193), and found 95 proteins 
interacting with SYK. In 12 of these, the gene expression change between LS and HS 
was over two-fold. These genes, together with SYK, were more frequently present 
in the GO-categories enriched in HS, when compared to those enriched in LS. 
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6 DISCUSSION
JNA is a rare tumour of unknown etiology. There is great variation between tumours 
regarding their tendency to grow and recur after surgical removal. The goal of 
this study was to investigate factors that settle the outcome of JNA management. 
First, we evaluated the used treatment modalities and their outcome in 27 JNA 
patients treated at the Helsinki University Central Hospital during the past 42 
years. This was highly important because during the last 10 years the management 
of JNA has undergone eminent evolution and new promising treatment modalities 
have been developed (38, 41, 57, 81, 98). We were able to show that the surgical 
approach used varied during the years and had an effect on the outcome of the 
patient. Other efforts were taken to clarify the effect of several proteins, known to 
act as growth and angiogenesis promoting factors in other tumours, to the vascular 
and cellular densities of JNA tumours, as well as to the stage of the tumours. We 
found that the expression of C-KIT correlated with cell density of the tumour, TNC 
expression correlated with vascular density of the tumour and TNC, GLUT-1 and 
SYK expressions correlated with the stage of the tumour. In addition, by comparing 
the altered gene copy number and gene expression levels of two phenotypically 
different JNA tumours, we seeked for processes putatively taking part in the more 
aggressive growth of some JNA tumours. 
The methods used in this study include the assessment of clinical data, the 
application of immunohistochemical stainings of paraffi n-embedded JNA samples, 
statistical methods and microarray techniques to investigate the gene copy number 
and gene expression level changes. The foremost limitaitons of this study were linked 
to the limited number of patients available, due to the rareness of this disease, 
affecting the statistical estimates, and the long duration of the study period putatively 
affecting the quality of the paraffi n-embedded samples. Also, in the 1970s the 
samples taken were smaller compared with the present practice. The comparison of 
different surgical techniques as such might be imprecise due to the fact that individual 
surgeons putatively had deviating prospects to perform a complete resection. The 
outcomes of different surgical approaches were estimated concerning the residual 
tumour or recurrence, the development of imaging techniques during the study 
period might have infl uenced the possibility to detect minimal residuals. 
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THE IMPACT OF SURGICAL APPROACH ON JNA’S TENDENCY TO PERSIST OR 
RECUR
For primary resection, transpalatal approach was most commonly (52%) used in 
the current series of 27 JNA patients. It was especially common during the earliest 
years of this material, as all patients during 1970–1989 were treated using either 
transpalatal (63%), a combination of transpalatal and transmaxillary (25%) or 
sublabial approach (13%). During the last decade of this study period, the use of 
other approaches gained popularity, as only 42% of the patients had exclusively 
transpalatal surgery. Although transpalatal approach is thought to be adequate 
to remove tumours limited to nasopharynx, nasal cavity and sphenoid sinuses, 
without scarring, it has obvious limitations. In the case of lateral tumour growth 
to pterygopalatine and infratemporal fossae (194), it has been connected with 
higher risk of recurrence. Consistent with earlier reports, transpalatal approach 
was observed to have a signifi cant risk of persistent disease and need of more than 
one re-surgery. Palatal fi stula is reported to be the most common complication 
of transpalatal approach and tends to heal spontaneously (194, 195). Despite the 
poor exposure for large tumours and the elevated rates of recurrence reported (6), 
transpalatal approach can be combined with other approaches in selected cases, 
as was done in three cases in this series. However, the advantage of combining 
transpalatal approach to other approaches also remains to be cleared, because two 
of these three cases were found to face recurrence after primary surgery. 
The high recurrence rates and other complications associated with open surgery 
have created pressure to work on new treatment modalities while, at the same 
time the evolution of imaging techniques has enabled the more precise planning 
of surgery. During the last decades, the transnasal endoscopic technique used for 
several other tumours has been put into operation also for JNA. In this series, 
only three patients were treated with endoscopic surgery, and one of these had a 
recurrence. It has been generally admitted that when resecting JNA endoscopically, 
high degree of skill in endoscopic surgery is mandatory and the surgeon should 
always be prepared to convert to an external approach, if necessary (58). Yet, in 
the 2000s numerous studies of endoscopic surgery have been encouraging, with 
satisfying outcomes and low recurrence rates. 
Initially, endoscopic approach was used exclusively for limited tumours 
presenting Stages I and II. Recently, however, also tumours with extensions into 
the pterygopalatal fossa, infratemporal fossa and even with limited intracranial 
involvement have been succesfully managed endoscopically (61, 79, 82), putatively 
due to increasing skills of operating surgeons. Inspite of this, consensus still remains 
that endoscopic surgery is not recommended for tumours with extensive extension 
into the cranium or laterally to the cavernous sinus (69, 73). The importance of 
exploring and carefully drilling the basis of the sphenoid has been emphasized by 
many authors as tumour invasion into the cancellous bone of this area has been 
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linked with higher risk of recurrence (5, 74, 84). It is thought that achieving of this 
area is easier with endoscopic resection (5, 74, 84), and the risk of recurrence of 
endoscopic resections is lower than in traditional approaches. The combination 
of endoscopic technique with an open approach allows delicate inspection of 
the surgical cavity, enables further resection and has been shown to reduce the 
likelihood of tumour recurrence (83). A promising new technique to make the 
endoscopic removal of JNA even more quick and effective, is the use of imaging 
guided navigation, which we tend to use in all JNA operative procedures for safety 
reasons and which has been suggested also by others (72). Furthermore, cavitron 
ultrasonic surgical aspirator (CUSA), preoperative use of intratumoural injections 
of cyanoacrylate glue (56) and notably the use of harmonic scalpel and coblation, 
might enable the resection of JNA without using preoperative embolization. 
Despite the fact that surgery is accepted to be the treatment of choise for 
JNA, the appropriate managing of the most advanced tumours with intracranial 
extensions remains controversial. Both the increased risk of recurrence and the 
potential morbidity related to intracranial surgery, are to be considered. Thus, some 
authors suggest that tumours with evidenced intracranial extension, or lesions 
estimated to be incompletely resectable, could be effectively cured with external 
beam radiotherapy without notable risk of morbidity (77, 92, 196). Surgery and 
radiotherapy have been shown to be evenly effective in the treatment of JNA (77), 
yet the complications of radiotherapy, such as sarcomatous transformation (14), 
endocrine hypofunction and cataract, should be carefully compared with the risks 
of intracranial surgery. 
In this series the recurrence rate was 37%, compatible with the average of 32% 
presented in the literature (65, 74, 83, 84). After the fi rst, seemingly complete tumour 
resection, recurrences were discovered on the average at 10.5 months. One factor that 
seemed to affect the possibility of recurrence in this material was the transpalatal 
approach used. In the literature, the extension of a tumour into lateral and superior 
directions has been shown to make surgical excision more diffi cult and with invasion 
to the skull base, recurrence rates of even 40–50% have been reported (83). Because 
of the unifocal and benign nature of JNA, recurrence is usually thought to represent 
a residual tumour due to incomplete resection and evident residual tumour has 
been shown to be an independent risk factor for recurrence. (84) Thus, it seems 
likely that the high recurrence rate associated with transpalatal approach has been a 
consequence of residual tumour left due to the too restricted approach used. Some 
authors also state that preoperative embolization might lead to incomplete resection, 
disrupting the tumour margins (5, 69). In this material, only 2 out of the 10 patients 
with recurrence were embolised. Also feeding vessels from the internal carotid 
artery are linked with higher risk of recurrence (84), probably due to the residual 
vascularization after embolization and thus impaired visibility or alternatively to 
the fact that these tumours have just extended more extensively. 
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YOUNG AGE LINKED TO POOR RECURRENCE-FREE SURVIVAL
Along with evident residual tumour, wide extension of the tumour likely to lead to 
residual tumour, embolization of the tumour according to some authors and feeding 
vessels from internal carotid artery, an other factor linked with recurrence in the 
literature is the patient’s young age at the time of the diagnosis (84). Also in this 
material, young age was linked with higher risk of recurrence, as only one out of 
nine patients over 17 years old had a recurrence (Figure V). The correlation between 
recurrence rate and young age of the patient has been presented in numerous studies 
(50, 83, 84), and JNA growth has been considered to relate with the hormonal 
environment during male puberty (9, 20, 85, 102). Although several studies have 
strove to demonstrate the precise role of androgen, estrogen and progesterone and 
their nuclear receptors in this tumour, the results still remain controversial (8–10). 
The use of nonsteroidal androgen receptor blocker fl utamide in the treatment of 
JNA has been reported in several studies with varying results. In their work with 
fi ve patients, Gates et al. showed a 44% decrease in tumour size after administering 
fl utamide (21), whereas Labra et al. found no effect of fl utamide in their 7 JNA 
patients (22). In the most recent study, Thackar et al. were able to show with their 
20 patients, that fl utamide-induced regression was demonstrated only in post-
pubertal patients (197). Earlier it has already been stated that in older patients, JNA 
tumours and tumour residuals are more likely to involute during follow up than in 
younger ones (2, 83). That is why in some patient populations, the “watchful waiting” 
might be a possibility, especially with tumour remnants in surgically challenging 
places. Yet, besides the patient’s age other factors predicting the residual tumour’s 
tendency to involute in progress, remain unknown. 
VASCULARITY OF JNA AFFECTING THE TUMOURS’ TENDENCY TO GROW LARGE
JNAs are known for their hypervascularity and studies investigating the proliferation 
of stromal and vascular components of JNA have raised interest regarding the 
hypothesis of the angiogenic growth factors taking a crucial part in the pathogenesis 
of this esoteric tumour (10, 18, 29, 121, 198, 199). In their immunohistochemical 
study, Brieger et al. showed that VEGF is secreted by cells of JNA (18) and in this 
material tumour vascularity was found to have a signifi cant correlation with tumour 
recurrence. These fi ndings are of great importance, since within the last decade 
increased understanding of the process of angiogenesis has enabled the development 
of new therapeutic substances. Studies presenting the important role of VEGF in the 
regulation of angiogenesis have allowed the blockade of VEGF signalling and made 
it a major target for the therapy of several tumours (200). In the present series, 
two cases with persistent tumour growth in the sphenoid bone, were successfully 
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experimentally treated with antiangiogenic drugs (selecoxib, thalidomide, etoposide) 
(98). In cancer therapy, the use of VEGF inhibitors is common (201), but so far none 
of our patients has been treated with these agents. Yet, in the future, this might be 
possible in selected JNA patients, knowing that JNAs are positive for VEGF.
TUMOUR SUPPRESSORS, ONCOGENES AND PROTO-ONCONGENES IN JNA
While most efforts aiming to elucidate the pathogenesis of JNA have been made to 
investigate growth factors, e.g., VEGF, transforming growth factor (TGF), insulinlike 
growth factor (IGF) and PDGF and platelet derived growth factor (PDGF) – all 
proteins known to be related to stromal or vascular growth and to correlate with 
high vessel density (10, 19, 29, 202, 203), fewer studies have been performed on 
actual tumour suppressors, oncogenes or proto-oncogenes. This might be due to the 
fact that inspite of its potential to aggressive behavior, JNA is classifi ed as a benign 
tumour. However, the expression of tumour suppressor adenomatous polyposis 
coli (APC) gene in JNA has been investigated in numerous studies, led by the 
discovery of increased frequency of JNA among patients with familial adenomatous 
polyposis (FAP) (25–27). The gene product of APC is known to regulate β-catenin, 
a downstream activator of the Wnt signalling pathway, as APC is needed for the 
degradation of β-catenin (25). Interestingly, β-catenin is known to act as a co-
activator of androgen receptors (ARs), increasing androgen sensitivity –possibly 
explaining the exclusive occurrence of JNA in adolescent males (28). None of the 
JNA patients in the current patient series had relatives with FAP or JNA (204).
Protein expressions of oncogene C-KIT and proto-oncogene C-MYC have been 
studied in JNA tissue and based on these fi ndings the possible involvement of 
these proteins in the growth and promotion on JNA has been discussed (29, 121, 
122, 129). Interestingly, in 2007 Sihto et al. investigated the expression of C-KIT 
in endothelial cells in several malignant tumours and concluded that it might 
be associated in tumour angiogenesis and furthermore in the development of 
morphologically characteristic features of coiled microvessels in certain juvenile 
brain tumours, as also in other tissues (118). They proposed hypoxia to be the 
triggering factor for C-KIT overexpression in tumour cells promoting angiogenesis 
and survival of tumour microvessel endothelial cells. C-MYC has also been thought 
to have a potential role in angiogenesis, as it induces fi broblasts to build up an 
immature vascular network of leaky, unstable blood vessels (132). Both observations 
are of great interest, because slit- and immature-like blood vessels are part of JNA’s 
histological architecture (15). 
In this study, frequent immunoexpression of C-MYC in stromal cells and C-KIT 
in both stromal and endothelial cells of JNA samples was shown. Interestingly, the 
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C-KIT expression was more abundant in the endothelium of slit-like vessels than in 
larger vessels. Endothelial C-KIT expression showed a signifi cant correlation to the 
cell density of the tumour and to the stromal expression of C-MYC. Based on these 
results, we ended up with a proposal that both the stromal and vascular component 
of JNA possibly take part in the neoplastic growth of the tumour. Additionally, the 
correlation between endothelial C-KIT and stromal C-MYC expression led to the 
hypothesis of stromal C-MYC putatively infl uencing the growth of immature blood 
vessels by regulating the expression and effect of C-KIT on endothelial cells. The 
role of these two proteins in JNA should, however, be elucidated. As a third known 
oncogene, the immunoexpression of BMI-1 in JNA samples was studied. This is 
an epigenetic silencing protein known to be dysregulated in many cancers and to 
correlate with poor prognosis (145, 147, 183). As far as we know, BMI-1 has not 
been studied in JNA tissue before. In this study, stromal cells frequently expressed 
BMI-1, suggesting that it might possibly be involved in the pathogenesis of JNA. 
However, no correlations between BMI-1 and the other proteins studied, or with 
clinical parameters, were found. 
To elucidate the possible formation of impaired capillaries, the immunoexpression 
of syndecan-2, a marker known to function as a co-receptor for growth factors and 
participate in numerous signalling cascades (169) was studied. In 2008, Noguer et al. 
demonstrated that syndecan-2 downregulation reduced the adhesion of endothelial 
cells leading to impaired formation of capillary vessels and enhanced migration 
of endothelial cells (170). In this fi nite material on JNA tumours, in the six cases 
when slit-like vessels lacked the syndecan-2 expression, the overall recurrence-free 
survival of these patients was worse, referring to the tendency of the tumour to 
recur and need of reoperations. This can be speculated to result from the absence 
of syndecan-2 leading to greater migration potential of endothelial cells, making 
radical surgical management more diffi cult, as the migrative endothelial cells have 
covered a wider boarder of the surgical fi eld.
TUMOUR- AND ANGIOGENESIS MARKERS IN JNA – ARE THEY PREDICTIVE?
Next, we aimed to fi nd proteins whose expression could predict the tendency of 
extensive tumour growth. Led by the fact that there are slit-like vessels without 
normal lumen in JNA tissue, and that phenotypes of this tumour vary so much, the 
aim was to test our hypothesis that part of JNAs are vascular malformations. This 
seemed warranted because the treatment of JNA still remains a challenge and more 
importantly, there are new treatment options available for lesions with vascular 
malformation characteristics. Infantile hemangiomas (IHs) are vascular tumours 
composed of endothelial cells without the ability to be organized in lumenized 
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structures. Tissue hypoxia is thought to precede the proliferative phase of IHs and 
this hypoxic insult contributes to the elevated levels of GLUT-1 in the lesion (148, 153, 
154). GLUT-1 is used in histopathological routine to distinguish hemangiomas from 
vascular malformations that do not express GLUT-1. The differentiation of these two 
entities is essential because only hemangiomas are self-limiting. Our aim was to test, 
if the high-stage JNA tumours were GLUT-1 negative and thus resembled vascular 
malformations. GLUT-1 negativity in our samples, however, did not show correlation 
with higher tumour stage and thus putatively more aggressive growth, often seen 
in vascular malformations. Quite on the contrary, endothelial GLUT-1 positivity, 
when present, was correlated with higher tumour stage. Based on this fi nding, it 
seems unlikely that JNAs or a part of them were vascular malformations. 
The fi nding of GLUT-1 expression correlating with higher tumour stage is 
somewhat compatible with literature, because GLUT-1 is known to be overexpressed 
in numerous neoplasms, especially in high grade tumours, as a marker of increased 
need of glucose metabolism in hypoxic lesions (77). The idea of possible hypoxia 
preceding the growth and angiogenesis of JNA has been presented (19). Hypoxia 
inducible factor (HIF)-1α expression data have been studied in two sets of JNA 
tumours and it can be concluded that HIF and its induced factors could be 
important in the promotion of JNA and maintenance on tumour cells (19, 198). 
In 2007 Schuon et al. investigated the HIF-1α expression in JNA and found it to 
be highest in well-vascularized tumours. They suggest that this is due to the fact 
that infunctional vessels cause the tumour to become hypoxic (19). HIF is known 
to be the main hypoxia signalling and VEGF activating transcription factor (205). 
Other downstream activation targets of HIFs are, e.g., GLUT-1, C-KIT and TNC 
(150, 151, 206, 207). 
TNC expression in adult tissues is known to be tightly regulated and restricted 
mostly to conditions requiring active remodelling, such as wound healing and 
infl ammation following tissue injury (208). However, it is known to be stromally re-
expressed in many tumours, and it acts as a predictive factor for local recurrence and 
mestatasis, e.g., in breast cancer, brain tumours and head and neck cancers (208). 
In addition, TNC has been classifi ed as a marker of vascular proliferation in lesions 
growing within brain tissue, and it has been proposed to stimulate angiogenesis by 
establishing tumour cell-derived vessels (209–211). Angiogenesis in tumours may 
be started by hypoxia, stromal and tumour cells or ECM compounds, resulting 
in leaky vessels, with only partial pericyte coverage (208, 212). TNC is thought to 
regulate angiogenesis by activating other factors, such as VEGF (213). However, 
taking part in remodelling of the ECM, TNC could have a direct effect in controlling 
of vascular instability of the tumour vessels (208, 212). Although most antiangiogenic 
treatments applied are targeted against VEGFs, in some tumours, these agents 
have been shown to actually promote metastasis, due to the resistance and escape 
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mechanisms (208, 212). This has led to the idea of redirecting the therapies against 
ECM proteins, such as TNC (214). Although the expression of VEGF and its receptor 
has been studied and demonstrated in JNA tissue, immunoexpression of TNC has 
not been previously studied in this tumour. In this material, TNC expression was 
frequent and correlated both with vessel density and higher tumour stage, as well 
as with GLUT-1, C-KIT and C-MYC.
As mentioned, Wnt/β-catenin pathway has been suggested to participate in 
the pathogenesis on JNA. The Wnt pathway is a proangiogenic pathway, leading 
to sprouting angiogenesis in several contexts, and various tumours (215, 216). 
By controlling the expression of Wnt antagonist, TNC has been shown to trigger 
this pathway (215, 216). C-MYC, C-KIT and GLUT-1 have been reported to act as 
downstream factors of the Wnt pathway, already suggested to act as a co-activator 
of AR in JNA tissue (28, 217–221). Thus, the Wnt pathway could serve as one 
putative connective link between the proteins, which in this series seemed predictive 
for JNAs growth by affecting cellular and vascular densities and the tumour stage 
(Figure VI). 
Figure VI. Our proposal for the activated Wnt-pathway (ON) – putatively triggered by TNC – regulating 
the expression of, e.g., C-MYC and TNC in JNA. The connection of androgen receptor (AR) to this pathway 
gives one possible explanation of why activated Wnt leads to growth promotion in JNA. 
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Another possible explanation is that hypoxia precedes the expression of GLUT-1, 
TNC and C-KIT and leads to increased vascularity and growth of JNA (Figure VII). 
Two recent studies have shown a connection between the expression of TNC and 
hypoxic conditions, as Gebb et al. showed hypoxia induced TNC expression to 
support branching morphogenesis of fetal lung explants and Koperek et al. found 
TNC to correlate with hypoxia and with lymph node metastasis of thyroid carcinomas 
(222, 223).
Figure VII. Our proposal for hypoxia induced HIF-pathway promoting the growth and angiogenesis of 
JNA, by upregulating the expression of, e.g., C-KIT, GLUT-1 and TNC.
This idea is supported by the discovery that HIF expression in JNA has been 
linked with high vascular densities (19). Interestingly, in colorectal cancer both 
Wnt signalling and HIF-1 signalling are reported to be essential in angiogenesis 
and growth of this tumour, by activating target proteins such as VEGF and C-MYC 
(224). Thus, it could be possible, that also in JNA pathogenesis, both these pathways 
could be essential. This, however, remains to be elucidated.
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THE PUTATIVE ROLE OF ALTERED GENE COPY NUMBERS AND GENE EXPRES-
SION LEVELS IN THE GROWTH OF JNA
To control the expression of genes essential to survival and tumour progression, a 
neoplastic cell population has the ability to change the copy numbers of these genes. 
These alterations usually involve a large group of closely located genes and only 
a minority of these truly participate in malignant growth (225–229). Integrating 
genome-wide copy number data with gene expression data is one way to identify 
the true oncogenic driver genes (230–232). A few genome-wide studies of copy 
number and gene expression changes in JNA have been reported. In one of them 
chromosomal alterations were studied separately for stromal and endothelial cells 
and most of the imbalances were detected in both components (28, 30, 94, 129, 
233–236). Although numerous chromosomal alterations have been demonstrated 
by these studies, explicit target genes for gains and deletions in JNA still remain 
unknown.
To achieve a wider vision of processes determining the different growth patterns 
and outcomes of JNA patients, we decided to explore the molecular genetic 
background of JNA by comparing gene copy number and gene expression level 
changes between two clinically different phenotypes of JNA of which we received 
fresh material. The two JNAs were both manifested in 15-year old male patients. One 
was an endoscopically removed, clearly limited tumour of 3 cm in diameter while 
the other was an extensive tumour infi ltrating intracranial space and warranting 
several surgical interventions, radiation treatment and antiangiogenic treatment. 
When analyzing the data, a few gene copy number changes that link to changes 
in gene expression were found. This might be due to the heterogeneity of the JNA 
tumour samples, consisting of, e.g., stromal, endothelial and epithelial cells. Another 
explanation for the low number of gene copy number changes is that in these 
subjects, the central level of regulation is not due to copy number abnormalities. 
1245 genes had a signifi cant, over two-fold change in their expression, between low 
and high stage JNA tumours. In these phenotypically different tumours, the in silico 
translated proteins of the differently expressed transcripts showed enrichement for 
different biological processes and functions. Genes over-expressed in the low stage 
tumour were commonly associated with biological functions linked to the tumour 
organization, like the development of the vasculature and epithelium, cell adhesion 
and collagen catabolic functions, and interestingly also hypoxia. On the contrary, in 
high-stage tumour with recurrences, the upregulated genes were associated with, 
e.g., signal transduction activity, including positive regulation of phosphorylation, 
tumour necrosis factor (TNF) production and Wnt-activated receptor activity. 
These results were in concordance with earlier immunohistochemical reports of, 
e.g., vascular growth factors, matrix metalloproteinases and HIFs being expressed 
in the JNA tissue (18, 19, 198, 202, 237). Based on the present results on gene 
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expression and prior knowledge of the proteins signifi cance for growth, we ended 
up investigating the immunoexpression of protein kinase SYK. SYK is a protein 
previously known to participate in tumourigenesis of different tumours and 
depending on the tumour, it can act as a tumour suppressor or as an oncogene (172). 
We found SYK expression to correlate with lower tumour stage also in JNA.
The possible connections of TNF and Wnt to the more aggressive growth 
pattern of JNA are of interest and should be confi rmed in the future. If the 
fi nding of TNF will be corroborated, it can offer a new treatment option for JNA, 
as TNF-targeted molecular therapies are already in wide use in immunological 
and cancer diseases (238, 239). The discovery of Wnt being putatively linked to 
the more aggressive growth of JNA is compatible with earlier reports of APC and 
β-catenin gene mutations and β-catenin protein expression in JNA, as well as with 
the suggestion that increased β-catenin expression might lead to increased AR 
sensitivity and thus explain the predominance of JNA in young boys (28). Also 
this observation supports our preliminary idea of Wnt possibly being the linking 
factor of the altered expression patterns of TNC, C-MYC, C-KIT and GLUT-1 in 
JNA, putatively promoting angiogenesis and growth in JNA, as presented earlier 
in this discussion. 
Since the incidence of JNA tumours is very low, all the molecular data published 
on this disease will be valuable in understanding the molecular genetic background of 
this esoteric tumour. In addition, the application of discovery-driven methodologies 
on diseases with unknown ethiologies can provide new hypotheses worth further 
analyses. This is of great importance because that learning novel aspects from 
molecular mechanisms of complex diseases, like JNA, can provide future targets 
for individual treatment strategies. 
CONCLUSIONS
This study was done to elucidate the factors and processes determing the variable 
outcomes of JNA. For this purpose we
- investigated the signifi cance of the treatment modalities used and of other clinical 
factors for tumour residuals and recurrent disease. The risk of recurrence in this 
series was linked with transpalatal approach, young age of the patient and vascular 
density of the tumour. These results emphasize the importance of choosing the right 
surgical approach for each case, other approaches probably being more preferable 
than transpalatal, at least for more extensive tumours. For selected cases, the 
consideration of antiangiogenic therapy could also be justifi ed by these results. 
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- studied the expressions of C-KIT, BMI-1, C-MYC, TNC, GLUT-1, syndecan-1 and 
2 and SYK in JNA samples and compared these with cell and vessel densities and 
tumour stage in order to investigate their putative signifi cance for JNA’s growth and 
vascularity. Endothelial C-KIT expression was found to correlate with cell density, 
proposing this protein to have a putative infl uence in JNA growth. Expression of 
stromal TNC was found to have a correlation with vessel density and higher tumour 
stage, as well as with numerous other factors, and it appears to have a role in 
tumourigenesis of JNA, possibly by promoting angiogenesis. The expression of SYK, 
a protein known to act as tumour suppressor in, e.g., breast cancer, was found to 
correlate with lower tumour stage in JNA. Based on our fi nding of GLUT-1 expression 
correlating with higher tumour stage, it seems unlikely that JNAs or even a part of 
them were vascular malformations. One explanation for our observation that the 
lack of syndecan-2 expression was linked with poorer recurrence-free survival could 
be that the loss of syndecan-2 expression leads to greater migration potential of 
tumour cells thus making the complete removal of JNA more diffi cult. 
- sought for processes determing the different outcomes of JNA by comparing 
the gene copy number and gene expression levels of two phenotypically different 
JNA tumours. By performing a gene ontology enrichement analysis for the in 
silico translated proteins with altered expression status, we were able to show that 
different processes were essential in low and high stage tumours. Certain interesting 
categories, among the ones with most enriched proteins, were, e.g., hypoxia in the 
low stage tumour and signal transduction activity in the high stage tumour. However, 
the assessing of clinically relevant molecular profi les of JNA still requires further 
characterization and because of the low frequency of JNA tumours, in the future, 
combining molecular profi ling data from several studies will be usefull to better 
undestrand the molecular background of this rare tumour. 
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